Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9326932 | 0.80 | LMNA (0.50) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL9748371 | 0.80 | LMNA (0.50) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL457881 | 0.78 | LMNA (0.48) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL29603165 | 0.76 | LMNA (0.46) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL16685452 | 0.76 | LMNA (0.46) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL9501106 | 0.75 | LMNA (0.50) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL28112526 | 0.74 | LMNA (0.39) | LMNAL3MBTL1TDP1KDM4E | |
| SCHEMBL28112532 | 0.74 | LMNA (0.39) | LMNAL3MBTL1TDP1KDM4E | |
| SCHEMBL8377780 | 0.71 | LMNA (0.46) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL29049145 | 0.71 | LMNA (0.46) | LMNAL3MBTL1TDP1KDM4EPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116761810-A | Imaging and targeting of programmed death ligand-1 (PD-L1) expression | 约翰霍普金斯大学 | 2023-09-15 | — | — | CN | claimed |
| US-20230271923-A1 | IMAGING AND TARGETING PROGRAMMED DEATH LIGAND-1 (PD-LI) EXPRESSION | THE JOHNS HOPKINS UNIVERSTY | 2023-08-31 | — | — | US | claimed |
| EP-4192524-A2 | IMAGING AND TARGETING PROGRAMMED DEATH LIGAND-1 (PD-LI) EXPRESSION | The Johns Hopkins University (US) | 2023-06-14 | — | — | EP | claimed |
| US-11607466-B2 | Tumor and immune cell imaging based on PD-L1 expression | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-03-21 | — | — | US | claimed |
| WO-2022032100-A2 | IMAGING AND TARGETING PROGRAMMED DEATH LIGAND-1 (PD-LI) EXPRESSION | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-02-10 | — | — | WO | claimed |
| EP-3558395-A1 | TUMOR AND IMMUNE CELL IMAGING BASED ON PD-L1 EXPRESSION | The Johns Hopkins University (US) | 2019-10-30 | — | — | EP | claimed |
| US-20190314531-A1 | TUMOR AND IMMUNE CELL IMAGING BASED ON PD-L1 EXPRESSION | THE JOHNS HOPKINS UNIVERSITY | 2019-10-17 | — | — | US | claimed |
| WO-2018119313-A1 | TUMOR AND IMMUNE CELL IMAGING BASED ON PD-L1 EXPRESSION | THE JOHNS HOPKINS UNIVERSITY (US) | 2018-06-28 | — | — | WO | claimed |
| CN-116761810-A | Imaging and targeting of programmed death ligand-1 (PD-L1) expression | 约翰霍普金斯大学 | 2023-09-15 | — | — | CN | disclosed |
| US-20230271923-A1 | IMAGING AND TARGETING PROGRAMMED DEATH LIGAND-1 (PD-LI) EXPRESSION | THE JOHNS HOPKINS UNIVERSTY | 2023-08-31 | — | — | US | disclosed |
| EP-4192524-A2 | IMAGING AND TARGETING PROGRAMMED DEATH LIGAND-1 (PD-LI) EXPRESSION | The Johns Hopkins University (US) | 2023-06-14 | — | — | EP | disclosed |
| US-11607466-B2 | Tumor and immune cell imaging based on PD-L1 expression | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-03-21 | — | — | US | disclosed |
| US-11268958-B2 | Bacteria-specific labeled substrtates as imaging biomarkers to diagnose, locate, and monitor infections | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-03-08 | — | — | US | disclosed |
| WO-2022032100-A2 | IMAGING AND TARGETING PROGRAMMED DEATH LIGAND-1 (PD-LI) EXPRESSION | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-02-10 | — | — | WO | disclosed |
| US-20190314531-A1 | TUMOR AND IMMUNE CELL IMAGING BASED ON PD-L1 EXPRESSION | THE JOHNS HOPKINS UNIVERSITY | 2019-10-17 | — | — | US | disclosed |
| WO-2018119313-A1 | TUMOR AND IMMUNE CELL IMAGING BASED ON PD-L1 EXPRESSION | THE JOHNS HOPKINS UNIVERSITY (US) | 2018-06-28 | — | — | WO | disclosed |
| US-20150250906-A1 | BACTERIA-SPECIFIC LABELED SUBSTRTATES AS IMAGING BIOMARKERS TO DIAGNOSE, LOCATE, AND MONITOR INFECTIONS | THE JOHNS HOPKINS UNIVERSITY | 2015-09-10 | — | — | US | disclosed |
| EP-2895205-A1 | BACTERIA-SPECIFIC LABELED SUBSTRATES AS IMAGING BIOMARKERS TO DIAGNOSE, LOCATE, AND MONITOR INFECTIONS | The Johns Hopkins University (US) | 2015-07-22 | — | — | EP | disclosed |
| WO-2014043606-A9 | BACTERIA-SPECIFIC LABELED SUBSTRTATES AS IMAGING BIOMARKERS TO DIAGNOSE, LOCATE, AND MONITOR INFECTIONS | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-05-22 | — | — | WO | disclosed |
| WO-2014043606-A1 | BACTERIA-SPECIFIC LABELED SUBSTRTATES AS IMAGING BIOMARKERS TO DIAGNOSE, LOCATE, AND MONITOR INFECTIONS | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11607466-B2 | Tumor and immune cell imaging based on PD-L1 expression | CD274, PDCD1LG2, PDCD1 | LMNA 2779/4885L3MBTL1 898/4885TDP1 1536/4885 |
| US-20190314531-A1 | TUMOR AND IMMUNE CELL IMAGING BASED ON PD-L1 EXPRESSION | CD274, PDCD1LG2, PDCD1 | LMNA 2779/4885L3MBTL1 898/4885TDP1 1536/4885 |
| US-20230271923-A1 | IMAGING AND TARGETING PROGRAMMED DEATH LIGAND-1 (PD-LI) EXPRESSION | CD274, PDCD1LG2, PDCD1 | LMNA 1146/4885L3MBTL1 377/4885TDP1 1516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.